HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study.
The introduction of HIV protease inhibitors was accompanied by reduction in HIV-associated opportunistic infections. Therefore, we performed a retrospective study of HIV-infected patients to evaluate the effects of therapy with an HIV protease inhibitor (PI) on oral candidosis. This was of special interest, because an important virulence factor of Candida albicans is the secreted aspartic protease (SAP), which is assigned to the same class of aspartic proteases as HIV protease. Sixty-two patients were examined five times over a period of 2 years. There was a hint at a difference in the frequencies of C. albicans carrier state and manifest oral candidosis in favour of treatment with a PI. In addition, loss of Candida colonization and manifest oral candidosis was observed only in patients with elevation of CD4 cells upon PI. This might explain the effect, which also might go back to a direct inhibition of yeast SAP.
Hoegl
L
L
Department of Dermatology, Ludwig Maximilians University, Munich, Germany.
Thoma-Greber
E
E
Röcken
M
M
Korting
H C
HC
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D002353:Carrier State / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors